Tsila Zuckerman1, Jacob M Rowe. 1. Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. t_zuckerman@rambam.health.gov.il
Abstract
PURPOSE OF REVIEW: Acute myeloid leukemia is a heterogeneous disease with a prognosis determined mostly by the leukemic karyotype. Allogeneic transplant in first remission is offered to patients with intermediate- and poor-risk cytogenetics. Only the minority of patients, however, have a matched sibling donor. RECENT FINDINGS: Matched unrelated, genetically haploidentical and umbilical cord blood have been increasingly used. Pros and cons of each procedure are discussed, and whenever available, comparisons are made. SUMMARY: With the progress made in supportive care and prophylaxis of graft-versus-host disease, significant improvement in results of transplant from alternative donors has enabled its increasing use in specific disease stages. The recommended transplant for a given patient and the timing of transplant are discussed.
PURPOSE OF REVIEW: Acute myeloid leukemia is a heterogeneous disease with a prognosis determined mostly by the leukemic karyotype. Allogeneic transplant in first remission is offered to patients with intermediate- and poor-risk cytogenetics. Only the minority of patients, however, have a matched sibling donor. RECENT FINDINGS: Matched unrelated, genetically haploidentical and umbilical cord blood have been increasingly used. Pros and cons of each procedure are discussed, and whenever available, comparisons are made. SUMMARY: With the progress made in supportive care and prophylaxis of graft-versus-host disease, significant improvement in results of transplant from alternative donors has enabled its increasing use in specific disease stages. The recommended transplant for a given patient and the timing of transplant are discussed.
Authors: Allison R Butts; Victoria T Brown; Lauren D McBride; Javier Bolaños-Meade; Amy W Bryk Journal: J Oncol Pharm Pract Date: 2015-03-22 Impact factor: 1.809
Authors: Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs Journal: Biol Blood Marrow Transplant Date: 2008-06 Impact factor: 5.742
Authors: J Peccatori; A Forcina; D Clerici; R Crocchiolo; L Vago; M T L Stanghellini; M Noviello; C Messina; A Crotta; A Assanelli; S Marktel; S Olek; S Mastaglio; F Giglio; L Crucitti; A Lorusso; E Guggiari; F Lunghi; M Carrabba; M Tassara; M Battaglia; A Ferraro; M R Carbone; G Oliveira; M G Roncarolo; S Rossini; M Bernardi; C Corti; M Marcatti; F Patriarca; M Zecca; F Locatelli; C Bordignon; K Fleischhauer; A Bondanza; C Bonini; F Ciceri Journal: Leukemia Date: 2014-06-04 Impact factor: 11.528
Authors: R B Walter; J M Pagel; T A Gooley; E W Petersdorf; M L Sorror; A E Woolfrey; J A Hansen; A I Salter; E Lansverk; F M Stewart; P V O'Donnell; F R Appelbaum Journal: Leukemia Date: 2010-05-20 Impact factor: 11.528